Uroplasty, Inc. (NYSE Amex:
UPI) highlighted results from a two-year, multicenter clinical study of
Macroplastique that will be published in the April 2010 print edition of The
Journal of Urology(R). The 24-month study evaluated the durability of
Macroplastique for stress urinary incontinence in women with previously
documented success at 12 months. Substantial, durable results were sustained
during 2 years with 84% of patients maintaining significant improvement from
their 12-month assessment. Additionally, 67% of the patients implanted with
Macroplastique were dry at the 24-month follow-up visit.
"This study clearly demonstrates that Macroplastique provides a high level
of long-term effectiveness," said Uroplasty Chief Executive Officer and
President David Kaysen. "The effectiveness means major improvements in quality
of life for women who previously suffered from unwanted urinary leakage.
While other urethral bulking agents may be absorbed into the body, potentially
diminishing their clinical benefit, Macroplastique is composed of a permanent
silicone elastomer that contributes to sustained, measurable patient
improvement," added Mr. Kaysen.
The study, titled "Durability of Urethral Bulking Agent Injection for
Female Stress Urinary Incontinence: 2-Year Multicenter Study Results" followed
67 Macroplastique patients with successful outcomes at 12 months for up to 24
months. Highlights of the study include: